MAPT and Alzheimer disease: Plasma GFAP levels have been shown to correlate with CSF GFAP levels and have greater accuracy than CSF GFAP levels in discriminating between Aβ–positive and Aβ-negative individuals, even at the preclinical stage [49], and influences the effects of Aβ on tau pathology in preclinical AD [53].